Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...
Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third-quarter financial results, Oppenheimer reaffirmed its Outperform rating ...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
(MENAFN- GlobeNewsWire - Nasdaq) -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust ...
CRISPR Therapeutics (CRSP) shares have seen considerable movement over the past month, leaving investors assessing what might be driving sentiment around this gene editing pioneer. With no recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback